Ozempic and Gastroparesis: What the FDA Warning Means

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Pharmacovigilance

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. For decades, pharmacovigilance systems have tracked rare but serious adverse effects of medications, building a foundation of safety knowledge. This page reviews the FDA's warning, the clinical evidence, and what it means for patients.

Bridging Legacy Health Literacy and Contemporary Safety Concerns

By bridging the gap between legacy health literacy and contemporary safety concerns, we can foster informed dialogue about the balance between therapeutic benefit and potential harm in mass production contexts. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, has been associated with GLP-1 receptor agonists, including Ozempic, through clinical reports and mechanistic plausibility. This narrative examines the clinical presentation and diagnosis of gastroparesis, the pharmacology of Ozempic and its reported adverse effects, mechanistic pathways linking the drug to gastroparesis, and risk considerations regarding warning adequacy, causation, and exposure timelines.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to nutritional deficiencies, weight loss, and impaired quality of life. In the context of Ozempic use, these symptoms overlap significantly with the drug's known gastrointestinal adverse reactions. The prescribing information for Ozempic reports that in placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight a dose-dependent increase in gastrointestinal symptoms, which are consistent with gastroparesis-like presentations.

Mechanistic Pathways Linking Ozempic to Gastroparesis

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying through activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, leading to reduced antral contractions and increased pyloric tone. This pharmacodynamic effect is intended to improve postprandial glycemic control but can result in delayed gastric emptying that mimics or exacerbates gastroparesis. The prescribing information lists pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The most common adverse reactions, reported in ≥5% of patients, include nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these symptoms overlap with gastroparesis, the label does not provide specific guidance on distinguishing drug-induced gastroparesis from other causes of gastrointestinal distress.

Risk Considerations: Warning Adequacy and Causation

Risk considerations for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The current prescribing information does not contain a dedicated warning for gastroparesis, despite the known effect of GLP-1 agonists on gastric emptying. This may lead to underrecognition of the condition in patients presenting with persistent nausea, vomiting, or abdominal pain during treatment. Causation-related considerations require careful evaluation of the temporal relationship between drug initiation and symptom onset. The majority of gastrointestinal adverse reactions occur during dose escalation, suggesting a dose-dependent effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop or persist even after dose stabilization. The timeline between exposure and documented harm can vary; some patients may experience symptoms within weeks of starting therapy, while others may develop delayed gastric emptying after prolonged use. Discontinuation of Ozempic often leads to resolution of symptoms, supporting a causal relationship. In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions that are consistent with gastroparesis, including nausea, vomiting, and abdominal pain. The mechanistic pathway involving delayed gastric emptying is well-established. However, the prescribing information does not explicitly warn about gastroparesis, which may affect patient awareness and clinical management. Patients experiencing persistent gastrointestinal symptoms while on Ozempic should be evaluated for gastroparesis, and clinicians should consider the drug as a potential cause. Further research is needed to clarify the incidence and risk factors for Ozempic-induced gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Ozempic and gastroparesis?

The FDA has updated the labeling for Ozempic to include reports of gastroparesis in patients exposed to the drug. However, the prescribing information does not contain a dedicated warning for gastroparesis, despite the known effect of GLP-1 agonists on gastric emptying. This may lead to underrecognition of the condition.

How does Ozempic cause gastroparesis?

Ozempic slows gastric emptying through activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, reducing antral contractions and increasing pyloric tone. This pharmacodynamic effect can result in delayed gastric emptying that mimics or exacerbates gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.